Search is not available for this dataset
Therapeutic
stringlengths 8
15
| Format
stringlengths 3
52
| CH1 Isotype
stringclasses 15
values | VD LC
stringclasses 9
values | Highest_Clin_Trial (Oct '21)
stringclasses 12
values | Est. Status
stringclasses 4
values | Heavy Sequence
stringlengths 2
132
| Light Sequence
stringlengths 2
113
| Heavy Sequence (if bispec)
stringlengths 2
132
| Light Sequence (if bispec)
stringlengths 2
112
| 100% SI Structure
stringlengths 7
224
⌀ | 99% SI Structure
stringlengths 7
364
⌀ | 95-98% SI Structure
stringlengths 7
207
⌀ | Year Proposed
int64 1.99k
2.02k
| Year Recommended
stringclasses 30
values | Target
stringlengths 2
75
| Companies
stringlengths 2
1.7k
| Conditions Approved
stringlengths 2
277
| Conditions Active
stringlengths 2
910
| Conditions Discontinued
stringlengths 2
384
⌀ | Development Tech
stringlengths 2
149
| Notes
stringlengths 8
194
⌀ | Heavy Sequence second
stringlengths 127
158
⌀ | Light Sequence second
stringlengths 116
136
⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tavolimab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGSALPWTFGQGTKVEIK | na | na | null | null | null | 2,016 | 2018 | TNFSF4 | European Network of Gynaecological Oncological Trial Groups;MedImmune | na | na | Ovarian cancer;Solid tumours | na | Tavolimab is the new name for Tavolixizumab (PL118) | QV QLQ ESGPGLVKPSQ TLSLTCAVY GGSFSSG YWNWIR KHPGKGL EYIGYISY NG ITYH NPSLK SRITIN RDTSKN QYSLQL NSVTPEDT AVYYCARYKY DYDGGHA MDY WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLNWYQ QKPGKAP KLLIYYT SKLHSGVPS R FSGSGSGTD YTLTIS SLQP EDFA TYYC QQGSALPW T FGQGT KVEI K |
Tebentafusp | scFv Fusion | na | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS | AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK | na | na | null | null | null | 2,017 | 2018 | CD3E | Immunocore;MedImmune | Uveal melanoma | Malignant melanoma | na | na | T-Beta section specific for PMEL peptide 280-288 presented by MH1 | E VQLVES GGG LV QPGG SLRLSC AASGY SFTGYTMNWVR QAPGKG LEWVALI NPYKGV STY NQKFKD RFTISVD KSKN TAYLQMN SLRAEDT AVYYCA RSGYYGDSD WYFDVW GQG TLVTVS S | AIQMTQSPSS LSA SVGD RVTITCR AS QDIRNYLNWYQ QKPGKAP KLLIYYTS RLESGVPS RF SGSGSGTD YTLTIS SLQP EDFA TYYC QQGNTLPW TF GQGT KVEI K |
Tebotelimab | Bispecific scFv with Crossover | G4;G4 | Kappa;Kappa | Phase-II/III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPDNGVTIYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREADYFYFDYWGQGTTLTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVSSVVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKLEIK | None;None | None;None | None;None | 2,019 | 2020 | PDCD1;LAG3 | MacroGenics | na | Gastic cancer;Oesophageal cancer;Head and neck cancer;Cholangiocarcinoma;Liver cancer;Haematological malignancies;Malignant melanoma;Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGYS FTSYWMNWVR QAPGQGL EWIGVI HPSDSET WL DQKFKD RVTITVD KSTS TAYMELS SLRSEDT AVYYCAR EHYGTSPF AYW GQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCRA SESVDNYGM SFMN W F QQKPGQPP KLLIHA ASNQGSGVPS R FSGSGSGTD FTLTIS SLEPED FAVYFC QQSKEVP YT FGGG TKVEI K |
Tecaginlimab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-I/II | Active | EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYIMHWVRQAPGQGLEWMGGIIPNNGGTSYNQKFQGRVTMTVDKSTSTGYMELSSLRSEDTAVYYCTRREVYGRNYYALDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASQGINNYLNWYQQKPGKAVKLLIYYTSSLHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYSNLPYTFGGGTKVEIK | EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDVGGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQGTLVTVSS | DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIK | None;None | None;None | None;None | 2,021 | 2022 | CD40;TNFRSF9 | Genmab | na | Solid tumours | na | na | null | E VQLVQ SGA EVK KPGA SVKVSC KTSGY TFTEYIMHWVR QAPGQG LEWMGGII PNNGGTSYNQK F QG RVTMTVD KSTST GYMELSS LRSEDT AVYYCTR R EV YGRN YYALDY WGQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITCS ASQG INNYLNWYQ QKPGK AVKLLIYYT SSLHSGVPSRFSGSGSGTD YTFTIS SLQ PEDIATYYCQQ YSNLPY T FGGGT KVEI K |
Teclistamab | Bispecific mAb | G4;G4 | Lambda;Lambda | Preregistration | Active | QLQLQESGPGLVKPSETLSLTCTVSGGSISSGSYFWGWIRQPPGKGLEWIGSIYYSGITYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHDGAVAGLFDYWGQGTLVTVSS | SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQPPGQAPVVVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEAVYYCQVWDSSSDHVVFGGGTKLTVL | EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL | None;None | None;None | None;None | 2,018 | 2019 | TNFRSF17;CD3E | Genmab;Janssen Research & Development | na | Multiple myeloma | na | na | null | QL QLQE SGPGL V KPSE TLSLTCTV SGGSISSGS YFWGWIR QPPGKGL EWIGSIYYS G ITYY NPSLKS RVTISVD TSKN QFSLKLSS VTAADT AVYYCA RHDGA VAGLFD YWGQG TLVTVS S | SY VLT QPPS VSV APGQ TARITC GGNNIGSK SVHWYQ QPPGQAP VVVVY DDSDRPSGIPE R FSGSNSGN TATLTISRVE AGDE AVYYCQVW DSSSD HVVFG GGT KLTV L |
Telazorlimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVTLKESGPALVKPTQTLTLTCSFSGFSLSTSGMGVGWIRQPPGKALEWIAHIWWDDDKYYNTALKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIDWDGFAYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWYQQKPGQAPRPWIYATSNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQWSSNPWTFGQGTKVEIK | na | na | null | null | null | 2,019 | 2020 | TNFRSF4 | Glenmark Pharmaceuticals | na | Atopic dermatitis;Systemic lupus erythematosus;Ulcerative colitis;Rheumatoid arthritis | na | na | null | Q VTLK ESGPA LV KPTQ TLTLTCSF SG FSLS TSGM GVGWIR QPPGKA LEWIAHIWW DDDKYYNTA LKTRLTIS KDTSKN QVVLTMT NMDPVDT ATYYCARI DWDGF AYW GQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASSS VSYMHWYQ QKPGQAPRP WIYAT SNRATGIP ARFS GSGSGTD YTLTISS LEPED FAVYYCQQ WSSNPWT F GQGT KVEI K |
Telisotuzumab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLANYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSESVDSYANSFLHWYQQKPGQPPKLLIYRASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPLTFGGGTKVEIK | na | na | null | null | null | 2,016 | 2017 | MET | Pierre Fabre;AbbVie | na | na | Solid tumours | na | null | Q VQLVQ SGA EVK KPGA SVKVSC KASG YIFTAYTMHWVR QAPGQG LEWMGWI KPNNGLA NYAQK FQG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCA RSEI TTEFDY WGQG TLVTV SS | D IVMT QSPDS LAVS LGE RATINC KSSES VDSYANSFLHWYQ QKPGQPP KLLIYRA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QSKEDPL T FGGG TKVEI K |
Temelimab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEMHWVRQAPGQGLEWIGAVAPETGGTAYNQKFKGRATITADKSTSTAYMELSSLRSEDTAVYYCTSTVVPFAYWGQGTLVTVSS | QIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKAWIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYQSLPLTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | MRSV envelope protein | GeNeuro | na | Multiple sclerosis;Type 1 diabetes mellitus;Chronic inflammatory demyelinating polyradiculoneuropathy | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TF TDY EMHWVRQ APGQG LEWIGAV APETGGTAYNQKFKG RATITA DKSTS TAYMELSS LRSEDT AVYYCT ST VVPFAY WGQG TLVTVS S | QI QLT QSPSS LSA SVGD RVTITCS ASSS VSYMYWYQ QKPGKAPK AWIYRT SNLASGVPS RF SGSGSGTD YTLTISS LQ PEDFAT YYC Q QYQSLP LTF GGG TKVEI K |
Tenatumomab | Whole mAb Radiolabelled | G2b | Kappa | Phase-I | Discontinued | EIQLQQSGPELVKPGASVKVSCKASGYAFTSYNMYWVKQSHGKSLEWIGYIDPYNGVTSYNQKFKGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCARGGGSIYYAMDYWGQGTSVTVSS | DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPLTFGAGTKLELK | na | na | null | null | null | 2,007 | 2008 | TNC | sigma-tau SpA | na | na | Cancer | na | null | EI QLQ QSGPE LV KPGA SVKVSCK ASGY AFTSYNMYWVK QSHGK SLEWIGYI DPYNGV TSY NQKFKG KATLTVD KSSS TAYMHLN SLTSEDS AVYYCA RGGG SIYYAMD YWGQG TSVTVS S | DI VMT QAAPSVPVTPGE SVSISC RSSK SLLH SNGN TYLYWFLQ RPGQSP QLLIYRM SNLASGVPDRFSGSGSGT AFTLRISRVE AEDV GVYYCMQH LEYP LTF GAGT KLEL K |
Teneliximab | Whole mAb | G1 | Kappa | Phase-II | ND | QIQLVQSGPELKKPGETVRISCKASGYAFTTTGMQWVQEMPGKGLKWIGWINTHSGVPKYVEDFKGRFAFSLETSANTAYLQISNLKNEDTATYFCVRSGNGNYDLAYFAYWGQGTLVTVSA | DIVLTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASHSISGIPSRFSGSGSGSDFTLSINSVEPEDVGIYYCQHGHSFPWTFGGGTKLEIK | na | na | 5dmi:HL | null | null | 2,002 | 2003 | CD40 | Bristol-Myers Squibb | na | Cancer | na | na | null | Q IQLVQ SGPELKKPGE TVRISCK ASG YAFT TTGM QWVQE MPGKGL KWIGWIN THSGVP KYVE DFKG RFAFSLET SANT AYLQIS NLKNEDT ATYFCVR SGNGN YDLAYFAYW GQG TLVTVS A | D IVLT QSPA TLSV TPGD RVSLSCR ASQS ISDYLHWYQQ KSHESP RLLIKYA SHS I SGIPSRFSGSGSGSD FTLSIN SVEPED VGIYYC QHGHSFPW TF GGGT KLEI K |
Teplizumab | Whole mAb | G1 | Kappa | Preregistration | Active | QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSS | DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT | na | na | null | null | null | 2,007 | 2008 | CD3E | Immune Tolerance Network;MacroGenics;National Institute of Diabetes and Digestive and Kidney Diseases;National Institutes of Health (USA);Provention Bio;Tolerance Therapeutics | na | Type 1 diabetes mellitus | Multiple sclerosis;Psoriasis;Psoriatic arthritis | na | null | Q VQLVQS GGG VV QPGR SLRLSCK ASGY TFTRYTMHWVRQ APGKG LEWIGYI NPSRGYTNYNQKVKD RFTISR DNSKN TAFLQM DSLRPEDT GVYFCARY YDDH YCLDY WGQGT PVTVS S | DI QMT QSPSS LSAS VGD RVTITCS ASSS VSYMNWY QQTPGKAPK RWIYD TSKLASGVPS RF SGSGSGT DYTFTISS LQ PEDIAT YYCQ QWSSNPF T FGQGT KLQI T |
Tepoditamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-I | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAKGTTGDWFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK | QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAIWYNARKQDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGTGYNWFDPWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK | None;None | None;None | None;None | 2,017 | 2018 | CLEC12A;CD3E | Genmab;Janssen Research & Development | na | na | Acute myeloid leukaemia;Myelodysplastic syndromes | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQG LEWMGII NPSGGSTSY AQKF QG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA KGTTGDW FDY WGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DF ATYYCQ QSYSTPPTFGQGT KVEI K |
Teprotumumab | Whole mAb | G1 | Kappa | Approved | Active | QVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPPWTFGQGTKVESK | na | na | null | null | null | 2,009 | 2010 | IGF1R | Genmab;Roche;Horizon Therapeutics plc | Graves ophthalmopathy | Diffuse scleroderma | Diabetic macular oedema;Advanced breast cancer;Hodgkin's disease;Non-Hodgkin's lymphoma;Non-small cell lung cancer;Sarcoma;Solid tumours | Medarex UltiMAb Mouse | null | Q VELVE SGGG VV QPGRSQ RLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAIIWF DGSST YYAD SVRG RFTISR DNSKN TLYLQMN SLRAEDT AVYFCA RE LGR R YFDL WGRG TLVSV SS | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSYL A W Y QQKPGQAP RLLIYD ASKRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSKWPPWTFGQGT KVE SK |
Teropavimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLLQSGAAVTKPGASVRVSCEASGYNIRDYFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRHASWDFDTFSFYMDLKALRSDDTAVYFCARQRSDYWDFDVWGSGTQVTVSS | DIQMTQSPSSLSASVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGVPSRFSGRRWGQEYNLTINNLQPEDIATYFCQVYEFVVPGTRLDLK | na | na | null | 4lsv:HL/4jpv:HL/5v8l:HL:GK:IM:GN/5v8m:HL:RT:SU/7ly9:HL:AM:EI:BC/7mxd:CD:JK:SU/7n28:CD:JK:SU/7pc2:GH:IJ:KL | null | 2,021 | 2022 | HIV-1 gp120 CD4bs | Gilead | na | HIV-1 | na | na | null | Q VQLLQ SGA AVT KPGA SVRVSCE ASGYNIR DYFIHWWR QAPGQG LQWVGWI NPKTGQPNNPRQ FQ G RVSLTR HAS W DFDT FSFYMDLKA LRSDDT AVYFCAR QRSDY WDFDVW GSG TQVTVS S | DIQ MT QSPSS LSA SVGD TVTITCQ ANGY LNWYQQ RRGKAP KLLIY DGSKLERGVPSRFSGRRWGQ EYNLTI NNLQ PEDIATYFCQVY EFV VPGT RLD LK |
Tesidolumab | Whole mAb | G1 | Lambda | Phase-II | Active | EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIGPFFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSS | SYELTQPLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVL | na | na | null | null | null | 2,014 | 2015 | C5 | MorphoSys;Novartis | na | Paroxysmal nocturnal haemoglobinuria | Choroiditis;Dry age-related macular degeneration;Panuveitis;Thrombotic microangiopathy;Wet age-related macular degeneration | MorphoSys HuCAL Phage Display;XmAb Engineering Technology | null | E VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWM GGIGPFFGTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCA RDTPYFDYWGQG TLVTV SS | SYELTQP LSVSVA LGQ TARITC SGDSIPN YYVYWYQ QKPGQAP VLVIY DDSNRPSGIPERFSGSNSGN TATLTISR AQAGDE ADYYCQSF DSSLN AEVF GGGT KLTV L |
Tesnatilimab | Whole mAb | G4 | Kappa | Phase-II | Active | QVHLQESGPGLVKPSETLSLTCTVSDDSISSYYWSWIRQPPGKGLEWIGHISYSGSANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCANWDDAFNIWGQGTMVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | na | na | null | null | null | 2,019 | 2020 | KLRK1 | Janssen Research & Development | na | Crohn's disease | na | na | null | Q VHLQE SGPGL V KPSE TLSLTCTV SDDSI SSYYWSWIR QPPGKGL EWIGHISYS GSANYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA NWDDAFN IW GQG TMVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYC Q QYGSSPWTFGQGT KVEI K |
Tezepelumab | Whole mAb | G2 | Lambda | Approved | Active | QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSS | SYVLTQPPSVSVAPGQTARITCGGNNLGSKSVHWYQQKPGQAPVLVVYDDSDRPSWIPERFSGSNSGNTATLTISRGEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL | na | na | 5j13:CB | null | null | 2,015 | 2016 | TSLP | Amgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia | Asthma | Atopic dermatitis;Rhinosinusitis;Chronic obstructive pulmonary disease | na | na | null | QM QLVES GGG VV QPGR SLRLSC AASGF TFRTYGMHWVRQ APGKG LEWVAVIWY DGSNKH YA DS V K GRFTITR DNSKN TLNLQMNSL RAEDT AVYYCA RAPQW ELVHEAFDI WGQG TMVTV SS | SY VL TQPPS VSV APGQ TARITC GGNNLGSK SVHWYQ QKPGQAP VLVVY DDSDRPSWIPERFSGSNSGN TATLTISR GEAGDE ADYYCQVWD SSSD HVVFG GGT KLTV L |
Tibulizumab | Bispecific Mixed mAb and scFv | G4;G4 | Kappa;Kappa | Phase-I | Discontinued | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK | QVQLVQSGAEVKKPGSSVKVSCKASGYKFTDYHIHWVRQAPGQCLEWMGVINPTYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS | DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGETYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGCGTKLEIK | None;None | None;None | None;6nou:AA/6nov:AB | 2,017 | 2018 | TNFSF13B;IL17A | Eli Lilly | na | na | Rheumatoid arthritis;Sjogren's syndrome | na | null | QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGKGL EWIGEIN HSGSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RGY YD ILTG YYYYFDY WGQG TLVTVS S | E IVLT QSPA TLSL SPGE RATLSCR ASQS VSRYLAWYQ QKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTDS TLTIS SLEPED FAVYYCQ QRSNWPRTFGQGT KVEI K |
Tidutamab | Bispecific Mixed mAb and scFv | G1;G1 | Kappa;Lambda | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMAWFRQAPGKGLEWVSFISNLGYSIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAPYDYDSFDPMDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRNRKNYLAWYQQKPDQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYYLWTFGGGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL | None;None | None;None | None;None | 2,018 | 2019 | SSTR2;CD3E | ICON;Xencor | na | na | Gastrointestinal stromal tumours;Neuroendocrine tumours | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF SDYG MAWFR QAPGKGL EWVSFI SNLGY SIYYA DSVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCA RAPYDYDSFDPMDYWGQG TLVTV SS | D IVMT QSPDS LAVS LGER ATINC KSS QSLL NSRNR KNYLAWYQ QKPDQSPK LLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC KQS YYLWTF GGG TKVEI K |
Tifcemalimab | Whole mAb | G4 | Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKLSCKASGYNFKHTYAHWVRQAPGQGLEWIGRIDPANGNTKYDPKFQGRATMTADTASNTAYLELSSLRSEDTAVYYCVADHYGSSLLDYWGQGTLVTVSS | DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTYFPYTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | BTLA | Shanghai Junshi Biosciences | na | Solid tumours | na | na | Chimeric. Tifcemalimab is the new name for Icatolimab (PL124) | Q VQLVQ SGA EVK KPGA SVKLSCK ASGYN FKHTYAHWVR QAPGQG LEWIGRI DPANGNTKYDPKFQG RATMTA DTASN TAYLELS SLRSEDT AVYYCVA DHYGSS LLDY WGQG TLVTVS S | DV VMT QTP LSLSV TPGQP ASISC KSSQ SLL DSDGK TYLNWFQ QRPGQSPR RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCW QGT Y FPY T FGQGT KLEI K |
Tigatuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK | na | na | null | null | null | 2,007 | 2008 | TNFRSF10B | Daiichi Sankyo Company;University of Alabama at Birmingham | na | na | Breast cancer;Colorectal cancer;Liver cancer;Lymphoma;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYVMSWVR QAPGKG LEWVATIS SGGS YTY YPDSVK GRFTISR DNAKN TLYLQMN SLRAEDT AVYYCAR RGDS MITT DYWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQDVG TAVAWYQ QKPGKAP KLLIYWA STRHTGVPSRFSGSGSGTD FTLTIS SLQP EDFAT YYC QQYSSY RTF GQGT KVEI K |
Tilavonemab | Whole mAb | G4 | Kappa | Phase-II | Active | EVKVVESGGGLVQPGGSMKLSCVVSGFTFSNYWVNWVRQAPGKGLEWVAQIRLKSDNYATHYEESVKGRFTISRDDSKSSVYLQMNNLRAEDSGIYYCTNWEDYWGQGTTVTVSS | DIVLTQSPDSLAVSLGERATISCRASQSVSTSRYSYIHWYQQKPGQPPKLLIKYASNLESGVPSRFSGSGSGTDFTLNIHPLEPEDFATYYCHHSWEIPLTFGQGTKLEIK | na | na | null | null | null | 2,018 | 2019 | MAPT | AbbVie;C2N Diagnostics | na | Alzheimer's disease;Progressive supranuclear palsy | na | na | Fixed missing FWL3 residue from Jan '22 release onwards | E VKVVES GGG LV QPGGS MKLSCVV SGF TF SN YWVNWVR QAPGKGL EWVAQIRLK SDNYAT HYEESV K GRFTIS RDDSKS SVYLQM NNLRAEDSG IYYC TNWEDYWGQG TTVTVS S | D IVLT QSPDS LAVS LGER ATISCR ASQSVSTSR YSYIHWYQ QKPGQPP KLLIKYA SNLESGVPS R FSGSGSGTD FTLNIH PLEP ED F ATYYC HHS WEIPLT FGQGT KLEI K |
Tildrakizumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK | na | na | null | null | null | 2,012 | 2013 | IL23A | Almirall S.A.;Merck & Co;Schering-Plough;Sun Pharmaceutical Industries | Plaque psoriasis | Ankylosing spondylitis;Intervertebral disc degeneration;Non-radiographic axial spondyloarthritis;Psoriatic arthritis | Autoimmune disorders | na | null | Q VQLVQ SGA EVK KPGA SVKVSC KASG YIFITYWMTWVR QAPGQG LEWMGQIF PASGSADYNEK F EG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCA RGGGG FAYW GQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR TSEN IYSYLAWY QQKPGKAP KLLIYN AK T LAEGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ HHYGIP FTF GQGT KVEI K |
Tilogotamab | Whole mAb | G1 | Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTHMHWVRQAPGQRLEWIGRIDPANGNTEYDQKFQGRVTITVDTSASTAYMELSSLRSEDTAVYYCARWGTNVYFAYWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKPWIYRTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYHSYPPTFGGGTKVEIK | na | na | null | 6t3j:CD:HI | null | 2,019 | 2020 | TNFRSF10B | Genmab | na | Solid tumours | na | na | (June '22) Corrected FWL4 sequence | Q VQLVQ SGA EVK KPGA SVKVSCK ASGF NI KDT HMHWVRQ APGQ RLEWIGRI DPANGNTEYDQ KF QG RVTITVD TSAST AYMELS SLRSEDT AVYYCAR WGTN VYFAYW GQG TLVTVS S | DI QLT QSPSS LSA SVGD RVTITCS ASSS VSYMYWYQ QKPGKAPKP WIYRT SNLASGVPS R FSGSGSGT DFTLTISS LQP EDFA TYYCQ QYHSYPPTFGGGT KVEI K |
Tilvestamab | Whole mAb | G1 | Kappa | Phase-I | Active | EVQLVESGGGLVQPGGSLRLSCAASGYSFTDFYINWVRQAPGKGLEWVARIFPGGDNTYYNEKFKGRFTLSADTSKSTAYLQMNSLRAEDTAVYYCARRGLYYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGIPYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQGTHVPPTFGQGTKVEIK | na | na | null | null | null | 2,019 | 2020 | AXL | BerGenBio | na | Cancer | na | na | (Feb '22) Removed erroneous W insertion from CDRH1. | E VQLVES GGG LV QPGG SLRLSC AASGYS F T DFYINWVR QAPGKG LEWVARI FPGGDNT YY NEKFKG RFTLSA DTSKS TAYLQM NSLRAEDT AVYYCA RRGL YYAMD YWGQG TLVTV SS | DI QMT QSPSS LSA SVGD RVTITCR SSQ SLVH SNGI PYLHWYQ QKPGKAP KLLIYRVS NRFSGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYC SQGTHVPPTFGQGT KVEI K |
Timigutuzumab | Whole mAb | G1 | Kappa | Phase-I | NFD | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | na | na | 1fvc:DC:BA/4hkz:BA/1n8z:BA/4ub0:HL/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC | 1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC | 5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL | 1,997 | 1998 | ERBB2 | Roche | Breast cancer | na | na | na | Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp and Anvatabart have identical V domains. | E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K |
Timolumab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFTFFSYAMHWVRQTPGKGLEWVAVIWFDGSNENYVDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDAWSYFDYWGQGTLVTVSS | VIQLTQSPSSLSASVGDRVTITCRASQGISRALAWYQQKPGKGPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK | na | na | null | null | null | 2,015 | 2016 | AOC3 | Acorda Therapeutics;Biotie Therapies Corp.;Seikagaku Corporation | na | na | Inflammation;Plaque psoriasis;Rheumatoid arthritis;Primary sclerosing cholangitis | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFFSYAMHWVRQ TPGKGL EWVAVIWF DGSNEN YVD SVKG RFTISR DNSKN TLYLQMNTL RAEDT AVYYCA RDAWS YFD YWGQG TLVTVS S | V IQLT QSPSS LSA SVGD RVTITCR ASQG ISRALAWYQ QKPGKGP KLLIYD ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGGT KVEI K |
Tinurilimab | Whole mAb | G2 | Kappa | Phase-I | Discontinued | QVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGIGVGWIRQPPGKALEWLAHIWWNDNKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARISLPYFDYWGQGTTLTVSS | DIQLTQSPSFLSASVGDRVTITCKASQNVGTAVAWYQQKPGKAPKLLIYSASNRYTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYSSYPLTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | CEACAM6 | Bayer;German Cancer Research Center | na | na | Solid tumours | na | null | Q VTLRE SGPA LV KPTQ TLTLTCTF SGF SL S TYGIGVGWIR QPPGKA LEWLAHIWW NDNKY Y STSL KTRLTIS KDTSKN QVVLTMT NMDPVDTA TYYCARIS LPYFDYWGQG TTLTVS S | DI QLT QSPS FLSA SVGD RVTITCK ASQNVG TAVAWYQ QKPGKAP KLLIYS ASNRYTGVPSRFSGSGSGT EFTLTIS SLQ PEDFATY YC QQYSSYP LTF GGG TKVEI K |
Tiragolumab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIK | na | na | null | null | null | 2,017 | 2018 | TIGIT | Genentech | na | Non-small cell lung cancer;Solid tumours;Oesophageal cancer;Small cell lung cancer;Squamous cell cancer;Cervical cancer;Liver cancer;B-cell lymphoma;Breast cancer;Multiple myeloma | na | na | null | EV QLQQ SGPGLVKPSQ TLSLTCAI SGDSVSSNS AAWNWIR QSPSRGL EW LGK TYYRFKWY SDY AVSVKGRITI NPDTSKN QFSLQL NSVTPEDT AVFYCT REST TYDL LAGPFDYWGQG TLVTVS S | D IVMT QSPDS LAVS LGE RATINC KSSQ TVLYS SNNK KYLAWYQ QKPGQPPN LLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQ YYSTPF TF GPGT KVEI K |
Tirnovetmab | Whole mAb (Canine) | G2 | Kappa | Unknown | Active | EVQLVESGPSLVKPGGSLRLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGITDYNPSLKSRITISRDTSKNQYYLQLNSVTTEDTATYYCARYGNYGYAMDYWGQGTSVTVSS | DIVMTQSPASLSVSLGQRATISCRASESVDTYGNSFMHWYQQKPGQSPKLLIYRASNLESGIPARFGGSGSGTDFTLTIDPVQADDVATYYCQQSYEDPWTFGGGTKLEIK | na | na | null | null | null | 2,020 | 2021 | IL31 (Canine) | Kindred Biosciences | na | Canine atopic dermatitis | na | na | null | E VQLVE SGPS LV KPGG SLRLTCSV TGDS ITS G YWNWIR KFPGNK LEYMGYISY SGITDYNPSLK SRITISR DTSKN QYYLQLNS V T TEDT ATYYCAR YGNYG YAMD YWGQGT SVTVS S | D IVMT QSPA SLSVS LGQ RATISCRA SESVDTYGN SFMHWYQ QKPGQSP KLLIYRA SNLESGIPA RF GGSGSGTD FTLTI DPVQADD VATYYCQ QSYEDPWTFGGG TKLEI K |
Tislelizumab | Whole mAb | G4 | Kappa | Approved | Active | QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSS | DIVMTQSPDSLAVSLGERATINCKSSESVSNDVAWYQQKPGQPPKLLINYAFHRFTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCHQAYSSPYTFGQGTKLEIK | na | na | 7bxa:BC:HL/7cgw:HL:AB | null | null | 2,017 | 2018 | PDCD1 | BeiGene;Celgene Corporation | Hodgkin's disease;Urogenital cancer | Gastric cancer;Liver cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Lung cancer;Lymphoma;Solid tumours;Ovarian cancer;Renal cancer | na | na | null | QV QLQE SGPGL V KPSE TLSLTCTV SG FSLTSYGVHWIR QPPGKGL EWIGVIYA DGSTNYNPSLK SRVTIS KDTSKN QVSLKLSS VTAADT AVYYCARA YGN YWYIDV WGQGT TVTVS S | D IVMT QSPDS LAVS LGE RATINC KSSESVSND VAWYQ QKPGQPP KLLINYAFHRF TGVPDRFSGSGYGTD FTLTISS LQAED VAVYYCH QAYSSPY T FGQGT KLEI K |
Tisotumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGDYTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSPWGYYLDSWGQGTLVTVSS | DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK | na | na | null | null | null | 2,015 | 2016 | F3 | Genmab;Seattle Genetics | Cervical cancer | Bladder cancer;Endometrial cancer;Fallopian tube cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Solid tumours | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFS NY AMSWVR QAPGKG LEWVSSI SGSGD YTYYT DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RSPWG YYL DSWGQG TLVTVS S | DIQ MT QSPPS LS ASAGD RVTITCR ASQGIS SRLAWY QQKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATY YC Q QYNSYPY T FGQGT KLEI K |
Tixagevimab | Whole mAb | G1 | Kappa | Approved | NFD | QMQLVQSGPEVKKPGTSVKVSCKASGFTFMSSAVQWVRQARGQRLEWIGWIVIGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSISCNDGFDIWGQGTMVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSRGWTFGQGTKVEIK | na | na | 7l7d:HL | 7l7e:AB:HL:IJ:TU | 7b0b:HL/7e3k:DE:HL:FG/7mm0:HL/7mlz:HL/7tbf:HL/7tb8:HL/7tcc:FG:JK:OP/7u0d:OP | 2,020 | 2021 | SARS-CoV-2 Spike RBD | AstraZeneca | COVID-19 | na | na | na | null | QM QLVQ SGPEVKKPGT SVKVSC KASGF TFMS SAVQ WVR Q ARGQR LEWIGWIVIG SGNTN YAQK FQE RVTITR DMSTST AYMELS SLRSEDT AVYYCA APYCSS IS CNDGF DIW GQG TMVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ HYGSSRG WTF GQGT KVEI K |
Tobemstomig | Bispecific mAb with Domain Crossover | G1;G1 | Kappa;Kappa | TBC | Active | EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK | EVQLLESGGGLVQPGGSLRLSCAASGFIFDDYTMNWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRFTISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTDTTLYGSDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSSPLTFGGGTKVEIK | None;None | None;None | None;None | 2,022 | na | PDCD1;LAG3 | TBC | TBC | TBC | TBC | TBC | null | E VQLLES GGG LV QPGG SLRLSCA ASGF SF S SYTMSWVR QAPGKG LEWVATIS GGGRD IY YPDSVK GRFTISR DNSKN TLYLQMNS LRAEDT AVYYCVLL TGR VYFALD SWGQG TLVTVS S | D IVMT QSPDS LAVS LGER ATINCK ASESVDTSDNS FIHWYQ QKPGQSP KLLIYR SSTLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QNYDVPW TF GQGT KVEI K |
Tobevibart | Whole mAb | G1 | Lambda | TBC | Active | ELQLVESGGGWVQPGGSQRLSCAASGRIFRSFYMSWVRQAPGKGLEWVATINQDGSEKLYVDSVKGRFTISRDNAKNSLFLQMNNLRVEDTAVYYCAAWSGNSGGMDVWGQGTTVSVSS | SYELTQPPSVSVSPGQTVSIPCSGDKLGNKNVAWFQHKPGQSPVLVIYEVKYRPSGIPERFSGSNSGNTATLTISGTQAMDEAAYFCQTFDSTTVVFGGGTRLTVL | na | na | null | null | null | 2,022 | na | HPV Envelope Protein | TBC | TBC | TBC | TBC | TBC | null | E LQLVES GGG WV QPGGSQ RLSC AASGR IFRSFYMSWVR QAPGKG LEWVATI NQDGS EKLYVD SVKG RFTISR DNAKNS LFLQM NNL RV EDT AVYYCAAW SGNSGGM DVW GQG TTVSVS S | SYELTQPPS VSV SPGQ TVSIP CSGDKLGN KNVAWFQ HKPGQSP VLVIYEVKY RPSGIPERFSGSNSGN TATLTIS GTQAMDE AAYFCQT FDST TVVF GGGT RLTV L |
Tocilizumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK | na | na | null | null | null | 2,004 | 2004 | IL6R | Assistance Publique Hopitaux de Paris;Charite - Universitatsmedizin Berlin;Chugai Pharmaceutical;Hospital for Special Surgery;JW Pharmaceutical;Roche;University Hospital Inselspital;University Hospital;Osaka University Tubingen;University of Bern;University of Pittsburgh | Drug hypersensitivity;Giant cell arteritis;Giant lymph node hyperplasia;Juvenile rheumatoid arthritis;Rheumatoid arthritis;Vasculitis | Adult-onset Still's disease;Osteoarthritis;Systemic scleroderma;Amyotrophic lateral sclerosis;Dermatomyositis;Familial Mediterranean fever;Polymyalgia rheumatica;Polymyositis;Pulmonary arterial hypertension;Schnitzler syndrome;Urogenital cancer | Chronic lymphocytic leukaemia;Ankylosing spondylitis;Crohn's disease;Multiple myeloma;Pancreatic cancer;Systemic lupus erythematosus | na | null | Q VQLQE SGPGL V RPSQ TLSLTCTV SG YSI TSDH AWSWVR QPPGRGL EWIGYISY SG ITTY NPSLKS RVTMLR DTSKN QFSLRLSS VTAADT AVYYCA RSLARTTAMDYWGQG SLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISSYLNWYQ QKPGKAP KLLIYYT SRLHSGVPSRFSGSGSGTD FTFTIS SLQ PEDIA TYYC QQGNTLP YT FGQGT KVEI K |
Tomaralimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVQSGSELKKPGASVKLSCKASGFTFTTYGINWVRQAPGQGLEWIGWIYPRDGSTNFNENFKDRATITVDTSASTAYMELSSLRSEDTAVYFCARLTGGTFLDYWGQGTTVTVSS | DIVLTQSPATLSLSPGERATLSCRASESVEYYGTSLMQWYQQKPGQPPKLLIFGASNVESGVPDRFSGSGSGTDFTLKISRVEAEDVGMYFCQQSRKLPWTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | TLR2 | Opsona Therapeutics | na | Delayed graft function;Myelodysplastic syndromes;Cancer | Autoimmune disorders;Inflammation | na | null | E VQLVQ SGS E LKKPGA SVKLSCK ASGF TFTTYGINWVRQ APGQG LEWIGWIY PRDGSTNFNENFKDR ATITVD TSAST AYMELS SLRSEDT AVYFCARL TGGT FLDY WGQG TTVTVS S | D IVLTQ SPA TLSL SPGE RATLSCR ASES VEYY GT SLMQWYQ QKPGQPP KLLIFG ASNVESGVPDRFSGSGSGTD FTLKISRVE AEDVG MYFCQ QSRKLPWTFGGGT KVEI K |
Tomuzotuximab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVST | DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK | na | na | null | 6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC/5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC | 5gz0:BA:DC/6arp:BA:DC/6aru:CB | 2,016 | 2017 | EGFR | Glycotope | na | Head and neck cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Renal cancer;Solid tumours | na | GlycoExpress Technology | null | QV QLKQ SGPGLVQPSQ SLSITCTV SGF SL T N Y GVHWVRQ SPGKGL EWLGVIWS GGNTDYNTPF TSRLSI NKDNSKS QVFFKM NSLQSNDT AIYYCA RAL TYY D YEFAYW GQG TLVTVS T | DI LLT QSP VILSV SPGE RVSFSCR ASQSIGT NIHWYQQ RTNGSP RLLIKYA SESISGIPSRFSGSGSGT DFTLSIN SVES EDIADYYCQ QNNNWPTTFGAGT KLEL K |
Toripalimab | Whole mAb | G4 | Kappa | Approved | Active | QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSS | DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK | na | na | 6jbt:HL | null | null | 2,018 | 2019 | PDCD1 | Fudan University;Peking University;Shanghai Junshi Biosciences;Sun Yat-Sen University | Malignant melanoma | Nasopharyngeal cancer;Oesophageal cancer;Biliary cancer;Gastric cancer;Non-small cell lung cancer;Solid tumours;Urogenital cancer;Head and neck cancer;Alveolar soft part sarcoma;Breast cancer;Cancer;Liver cancer;Lymphoma;Neuroendocrine tumours;Renal cancer | na | na | null | QGQ LVQ SGA EVK KPGA SVKVSCK ASGY TF TDY EMHWVRQ APIHG LEWIGVIES ETGGTAYNQK F K GRVTITA DKSTS TAYMELS SLRSEDT AVYYCA REGI TTVATTYYWYFDV WGQG TTVTVS S | DV VMT QSPLSLP VT LGQP ASISC RSSQ SIVH SNGN TYLEWYL QKPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVP LTF GQGT KLEI K |
Torudokimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVETGGGLIQPGGSLRLSCAASGFTFSFYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTIHGIRAAYDAFIIWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVGINLSWYQQKPGQAPRLLIYGASHRLTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYSQPPPFTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | IL33 | Eli Lilly | na | Atopic dermatitis | na | na | null | E VQLVET GGG LI QPGG SLRLSCA ASGF TFSFYAMSWVR QAPGKG LEWVSAIS GSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA R T IHGIRAA YD AFIIW GQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQS VGINLSWY QQKPGQAP RLLIYG ASH RL TGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCHQ YSQPPPF TF GGG TKVEI K |
Tosatoxumab | Whole mAb | G1 | Lambda | Phase-III | Active | EVQMVQSGAEVKKPGEPLKISCKGSGYKFGTHWIGWVRQRPGKGLEWMGIIHPADSETKYSPSFQGQVSFSADKSSNTAYLHWSTLRASDTAMYYCARRSGSSSWYALDFWGQGTMVTVSS | QSVLTQSPSASGTPGQRVTISCSGGSSNIGSNTVNWYQQFPGAAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGLYVFGTGTKVTVL | na | na | null | null | null | 2,013 | 2014 | Toxin A | Aridis Pharmaceuticals;Kenta Biotech | na | Nosocomial pneumonia | Sepsis | na | null | E VQMVQ SGA EVK KPGEP LKISC KGSGYKFGT HWIGWVRQ RPGKGL EWMGII HPADSETKYSPSFQG QVSFSA DKSSN TAYLHWSTL RASDT AMYYCAR RSGSSS WYALDF WGQG TMVTVS S | QSV LT QSPSASGTPGQ RVTISC SGGSSNIG SNTVNWYQQ FPGAAP KLLIYT NNQRPSGVPDRFSGSKSGT SASLAIS GLQSEDEAD YYCATW DDSLNG LYVF GTGT KVTV L |
Tovetumab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK | na | na | null | null | null | 2,013 | 2014 | PDGFRA | Cambridge Antibody Technology;MedImmune | na | na | Glioblastoma;Non-small cell lung cancer;Solid tumours | na | null | Q VQLVES GGG LV KPGG SLRLSC AASGF TF SDYYMNWI R QAPGKGL EWVSYI SSSGS IIYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REG RIAARGMDV WGQG TTVTVS S | DIQMTQSPSS LSA SVGD RVSITC RPSQS FSRYINWYQ QKPGKAP KLLIHA ASSLVGGVPSRFSGSGSGTD FTLTIS SLQP EDFA TYYCQ QTYSNPPI TF GQGT RLE MK |
Tozorakimab | Whole mAb | G1 | Lambda | Phase-III | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISAIDQSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQKFMQLWGGGLRYPFGYWGQGTMVTVSS | SYVLTQPPSVSVSPGQTASITCSGEGMGDKYAAWYQQKPGQSPVLVIYRDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCGVIQDNTGVFGGGTKLTVL | na | na | null | null | null | 2,020 | 2021 | IL33 | AstraZeneca | na | Chronic Obstructive Pulmonary Disease;Diabetic nephropathy | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVS GI SAI DQST YY ADSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARQKFMQL WGGGLRYPFGYWGQG TMVTVS S | SY VLT QPPS VSV SPGQ TASITC SGEGMGDK YAAWYQ QKPGQSP VLVIYR DTKRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCGVIQ DNTG VF GGGT KLTV L |
Tralokinumab | Whole mAb | G4 | Lambda | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS | SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL | na | na | 5l6y:HL | null | null | 2,009 | 2010 | IL13 | Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune | na | Atopic dermatitis;Alopecia areata | Asthma;Chronic obstructive pulmonary disease;Idiopathic pulmonary fibrosis;Ulcerative colitis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYGLSWVRQ APGQGL EWMGWISA NNGDTNYGQ EFQGRVTMTT DTSTS TAYMELRSL RSDDT AVYYCA RDSSSS W ARWFFD LWGRG TLVTV SS | SY VL TQPPS VSV APGK TARITC GGN II G SK L VHWYQ QKPGQAP VLVIY DDGDRPSGIPERFSGSNSGN TATLTISRVE AGDE ADYYCQVWD TGSDP VVF GGGT KLTV L |
Trastuzumab | Whole mAb | G1 | Kappa | Approved | NFD | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | na | na | 1fvc:DC:BA/4hkz:BA/4ub0:HL/5xhf:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC | 1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC | 5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL | 1,997 | 1998 | ERBB2 | Roche | Breast cancer | na | na | na | Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp and Anvatabart have identical V domains. | E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K |
Tregalizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EEQLVESGGGLVKPGGSLRLSCAASGFSFSDCRMYWLRQAPGKGLEWIGVISVKSENYGANYAESVRGRFTISRDDSKNTVYLQMNSLKTEDTAVYYCSASYYRYDVGAWFAYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSYIYWYQQKPGQPPKLLIYLASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRELPWTFGQGTKVEIK | na | na | null | null | null | 2,010 | 2011 | CD4 | Biotest AG | na | na | Multiple sclerosis;Plaque psoriasis;Rheumatoid arthritis | na | null | EE QLVES GGG LV KPGG SLRLSCA ASGFSFSDC RMYWLRQ APGKGL EWIGVISVK SENYGANYAE SVRGRFTISR DDSKN TVYLQMN SLKTEDT AVYYCSASYYRY DVG AWFAYW GQG TLVTVS S | D IVMT QSPDS LAVS LGER ATINCR ASKSVSTSGY SYIYWYQ QKPGQPP KLLIYLASIL ESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QHSRELPW T FGQGT KVEI K |
Tremelimumab | Whole mAb | G2 | Kappa | Preregistration | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK | na | na | 5ggu:HL:AB/5ggv:HL | null | null | 2,005 | 2008 | CTLA4 | AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine | na | Head and neck cancer;Liver cancer;Mesothelioma;Non-small cell lung cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer | Diffuse large B-cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes | Abgenix XenoMouse | Tremelimumab is the new name for Ticilimumab (PL97) | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCAR DPRGA TLYYYYY G M DVWGQG TTVTVS S | DIQ M TQSPSS LSA SVGD RVTITCR ASQS INSYLDWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YYSTPF T FGPGT KVEI K |
Trevogrumab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQVLESGGDLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSAISGSGGSAYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKDGAWKMSGLDVWGQGTTVIVSS | DIQMTQSPASLSASVGDRVTITCRASQDISDYLAWYQQKPGKIPRLLIYTTSTLQSGVPSRFRGSGSGTDFTLTISSLQPEDVATYYCQKYDSAPLTFGGGTKVEIK | na | na | null | null | null | 2,015 | 2016 | MSTN | Regeneron Pharmaceuticals;Sanofi | na | Muscular atrophy;Osteoporosis | na | VelocImmune Mouse | null | E VQVLE SGGD LV QPGG SLRLSC AASGF TFSAYAMTWVR QAPGKG LEWVSAIS GSGGS AYYA DSVKG RFTISR DNSKN TVYLQMN SLRAED TAVYYC AKDGA WKMSGLDVW GQG TTVIVS S | DIQMTQSPA SLSAS VGD RVTITCR ASQD ISDYLAWYQ QKPGKIP RLLIYT TSTLQSGVPSRFRGSGSGTD FTLTIS SLQ PEDVATYYCQK YDSAP LTF GGGT KVEI K |
Trinbelimab | Whole mAb | G1 | Lambda | TBC | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGIFRTYAISWVRQAPGQGLEWMGGIIPMFGTVNYAQKFQGRVTISADKSTSTAYMELSRLRSEDTAVYYCARPPSGGCGGDCSRRGYYYAMDVWGQGTTITVSS | QSALTQPASVSGSPGQSITISCSGSSSDVGGYKYVSWYQQHPGKAPQLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGGGTKLTVL | na | na | null | null | null | 2,021 | 2022 | RhD | Bharat Serums and Vaccines | TBC | TBC | TBC | na | (June '22: Corrected CDRH3 sequence) | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGI FRTYAISWVR QAPGQGL EWM GG IIPM FG TVNY AQKFQG RVTISA DKSTS TAYMELSR LRSEDT AVYYCA RPPSGGCGGDCSRRG YYYAMD VWGQG TTITVS S | QSALTQPA SV SGSPGQ SITISC SGSSSDVGG YKYVSWYQ QHPGKAP QLMIYD VNNRPSGV SN RFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTSSST RVF GGGT KLTV L |
Trontinemab | Bispecific Mixed Format with Domain Crossover | G1;G1 | Kappa;Kappa | TBC | Active | QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS | DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK | QSMQESGPGLVKPSQTLSLTCTVSGFSLSSYAMSWIRQHPGKGLEWIGYIWSGGSTDYASWAKSRVTISKTSTTVSLKLSSVTAADTAVYYCARRYGTSYPDYGDASGFDPWGQGTLVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQSISSYLAWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNYASSNVDNTFGGGTKVEIK | 5csz:AB:HL;None | None;None | None;None | 2,022 | na | APP Abeta 1-40/42;TFRC | TBC | TBC | TBC | TBC | TBC | Arm 1 has same Fv as Gantenerumab | Q VELVE SGGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAI NASGT RTYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA RGKGNTHKPY GYVRYFDV WGQG TLVTVS S | D IVLTQ SPA TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGVP ARFS GSGSGT DFTLTIS SLE PEDFAT YYCLQIY NMP ITF GQGT KVEI K |
Tucotuzumab | Whole mAb ADC | G1 | Kappa | Phase-II | Discontinued | EIQLVQSGAEVKKPGETVKISCKASGYTFTNYGMNWVKQTPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSTSTAFLQINNLRSEDTATYFCVRFISKGDYWGQGTSVTVSS | EIVLTQSPATLSLSPGERVTLTCSASSSVSYMLWYQQKPGSSPKPWIFDTSNLASGFPARFSGSGSGTSYSLIISSMEAEDAATYYCHQRSGYPYTFGGGTKLEIK | na | na | null | null | null | 2,005 | 2006 | EPCAM | EMD Lexigen;Merck KGaA | na | na | Ovarian cancer;Small cell lung cancer | na | null | E IQLVQ SGA EVK KPGE TVKISCK ASGY TFTN YGM NWVK QTPGKGL KWMGWIN TYTGEPTYADDFKG RFAFSLE TSTST AFLQIN NLRSEDTA TYFCVRFIS KGDYWGQG TSVTVS S | E IVLTQ SPA TLSL SPGE RVTLTCS ASSS VSYMLWYQ QKPGSSPKP WIFD TSNLASGFP ARFS GSGSGT SYSLIISS MEAED AA TYYCH QRSGYPY TF GGGT KLEI K |
Tulisokibart | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGFDIQDTYMHWVKQRPGQGLEWMGRIDPASGHTKYDPKFQVRVTITRDTSTSTVYLELSSLRSEDTAVYYCARSGGLPDVWGQGTTVTVSS | EIVLTQSPGTLSLSPGERATLSCRASSSVSYMYWYQQKPGQAPRPLIYATSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWEGNPRTFGGGTKLEIK | na | na | null | null | null | 2,022 | na | TNFSF15 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGFDIQDT YMHWVK QRPGQG LEWMGRI DPASGHTKYDPKF QVRVTITR DTSTS TVYLELS SLRSEDT AVYYCA RSGGLPDVWGQG TTVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASSS VSYMYWYQ QKPGQAPRP LIYAT SNLASGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQQ WEGNPRTFGGG TKLEI K |
Tuparstobart | Whole mAb | G1 | Kappa | TBC | Active | QVQMVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQGLEWMGEIDPANDNTKYDPKFQGRVTITADTSTSTVYMELSSLRSEDTAVYYCATYYYKYDVGGFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCSVSSSISSSNLHWYQQKPGQAPRLLIYGTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWSSYPFTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | LAG3 | TBC | TBC | TBC | TBC | TBC | null | Q VQMVQ SGA EVK KPGA SVKVSCK ASGFNIKD TYIHWVRQ APGQG LEWMGEI DPANDNTKYDPKFQG RVTITA DTSTS TVYMELS SLRSEDT AVYYCATYYYKY DVGGF DY WGQG TLVTVS S | E IVLTQ SPG TLSL SPGER ATLSCSVS SSISSSNL HWYQ QKPGQAP RLLIYG TSNLASGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QWSSYPF TF GQGT KVEI K |
Tusamitamab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQTPERGLEWVAYISSGGGITYAPSTVKGRFTVSRDNAKNTLYLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTVSS | DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKPGKSPKLLVYNTRTLAEGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQHHYGTPFTFGSGTKLEIK | na | na | null | null | null | 2,020 | 2021 | CEACAM5 | Sanofi-Aventis | na | Non-small cell lung cancer;Breast cancer;Pancreatic cancer;Solid tumours | na | na | null | EV QLQ ESGPG LV KPGG SLSLSC AASG FVFSS YDM SWVR QTPERGL EWVAYIS SGGG ITY APSTV KGRFTVSR DNAKN TLYLQMN SLTSEDT AVYYCAAHY FGSSGP FAYW GQG TLVTV SS | DIQ MT QSPA SLSAS VGD RVTITCR ASEN IF SYLAWY QQKPGKSP KLLVYN TRTLAEGVPSRFSGSGSGTD FSLTIS SLQ PEDFAT YYCQ HHYGTPF TF GSGT KLEI K |
Tuvonralimab | Whole mAb | G1 | Kappa | Phase-I | Active | QVQLVESGGGVVEPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYKPSEKDYADSAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGLLGYFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSINSYLAWYQQKPGQAPRPLIYGVSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRYPFTFGPGTKVDIK | na | na | null | null | null | 2,021 | 2022 | CTLA4 | Qilu Puget Sound Biotherapeutics | na | Neoplasms | na | na | null | Q VQLVES GG GVV EPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWYK PSEKDYADSAKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARGG LLGYFD YWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQS INSYLAWYQ QKPGQAPRP LIYGVS SRATGIPDRFSGSGSGTD FTLTISR LE PEDF AVYYC QQ YGRYPF TF GPGT KVDI K |
Ubamatamab | Bispecific mAb | G4;G4 | Kappa | Phase-I/II | Active | QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYYMSWVRQAPGKGLEWISYISGRGSTIFYADSVKGRITISRDNAKNSLFLQMNSLRAEDTAVYFCVKDRGGYSPYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK | EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSKGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYHYGLDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK | None;None | None;None | None;None | 2,021 | 2022 | MUC16;CD3E | Regeneron Pharmaceuticals | na | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer | na | na | null | Q VQLVES GGG LV KPGG SLRLSC AASGF TFS N YYMSWVR QAPGKGL EWISYI SGRGS TIFYAD SVKG RITISR DNAKNS LFLQMN SLRAEDT AVYFCVK DRGGYSPYWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISTYLNWYQ QKPGKAP KLLIYT ASSLQSGVPSRFSGSGSGTD FTLTIS SLQP EDFAT YYC QQSYSTPP ITF GQGT RLEI K |
Ublituximab | Whole mAb | G1 | Kappa | Preregistration | Active | QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS | QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIK | na | na | null | null | null | 2,010 | 2011 | MS4A1 | LFB Biotechnologies;rEVO Biologics;Johns Hopkins University;TG Therapeutics Inc | na | Chronic lymphocytic leukaemia;Multiple sclerosis;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma | Neuromyelitis optica | EMABling Platform | null | QA YLQ QSGA ELV RPGA SVKMSCK ASGY TFTSYNMHWVK QTPRQGL EWIGGI YPGNGDTSYNQKFKG KATLTV GKSSST AYMQLS SLTSEDS AVYFCARY DYNYA M DYWGQG TSVTVS S | Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYMHWYQ QKPGSSPKP WIYAT SNLASGVP ARFS GSGSGT SYSFTISRVE AEDA ATYYCQQWTF NPPTFGGG TRLEI K |
Ulenistamab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQGLEWMGWIDPENGNTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARRAITTATAWFAYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYNLYTFGQGTKVEIK | na | na | null | null | null | 2,021 | 2022 | PAUF | Prestige Biopharma | na | Pancreatic cancer;Ovarian cancer | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGFNIK D YYMHWVR QAPGQGL EWMGWI DPENGNTNY AQKF QG RVTMT RDTS ISTAYME LS RLRSDDT A VYY CARRAITTATAWFA Y WGQG TLVTVS S | D IVMT QSPDS LAVS LGER ATINC KSSQ SLL NSRTR KNYLAWYQ QKPGQPP KLLIYWA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC KQSY NLYTF GQGT KVEI K |
Uliledlimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLQESGPGLVKPSETLSLTCAVSGYSITSGYYWNWIRQPPGKKLEWMGYINYGGSNGYNPSLKSRITISRDTSKNQFSLKLSSVTAADTAVYYCARDYDAYYEALDDWGQGTTVTVSS | EIVLSQSPATLSLSPGERATLSCRASSRVNYMHWYQQKPGQSPRPWISATSNLASGVPARFSGSGSGTSYTLTISSLEPEDFAVYYCQQWSSNPPTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | NT5E | TRACON Pharmaceuticals;I-Mab Biopharma | na | Breast cancer;Gastrointestinal cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Solid tumours | na | na | null | EV QLQ ESGPGL V KPSE TLSLTCAV SGY SIT SG YYWNWIR QPPGK KLEWMGYINY GGSNGYNPSLK SRITISR DTSKN QFSLKLSS VTAADT AVYYCA RDY DAYYEAL DDWGQGT TVTV SS | E IVLS QSPA TLSL SPGE RATLSCRA SSRV NYMHWYQ QKPGQSPRP WISA TSNLASGVP ARFS GSGSGT SYTLTISS LEPED FAVYYCQQ WSSNPPTFGGG TKVEI K |
Ulocuplumab | Whole mAb | G4 | Kappa | Phase-I/II | Active | EVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIK | na | na | null | null | null | 2,013 | 2014 | CXCR4 | Bristol-Myers Squibb;Medarex;University of Bari | na | Acute myeloid leukaemia;Solid tumours;Waldenstrom's macroglobulinaemia;Neuroectodermal tumours | B-cell lymphoma;B-cell prolymphocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Multiple myeloma | na | null | E VQLVES GGG LV QPGG SLRLSC AAAG FTFSS Y SMNWVR QAPGKGL EWVSYIS SRSR TIYYA DSVKG RFTISR DNAKNS LYLQMN SLRDEDT AVYYCAR DYGGQPP YYYYYGMDV WGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISSWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQPE D FVTYYCQ QYNSYPRTFGQGT KVEI K |
Ulviprubart | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDHNMHWVKQATGQGLEWFGFINPNTGVTRYNQKFQGRVTLTINKAISTAYLELSSLRSEDTAVYYCARDYYGSAWFAYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQTLLYSSDQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYNYPTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | KLRG1 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TF TDHN MHWVKQ ATGQGL EWFGFI NPNTG VTRY NQKFQG RVTLTI NKAI STAYLELS SLRSEDT AVYYCAR DYYGS AWFAYW GQG TLVTVS S | D IVMT QSPDS LAVS LGE RATINC KSSQ TLLYS SDQKN YLAWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQ YYNYPTFGGG TKVEI K |
Umesolerbart | Whole mAb | G4 | Kappa | TBC | Active | EVQLVESGGDLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSFISDSSSNIYYADSVKGRFTISRDNAKKSLYLQMTSLRAEDTAVYYCAREAIGSTSFDNWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVSSSLAWYQQKPGQAPRRLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAIYYCHQYNNWPLTFGGGTKVEIK | na | na | 7mxl:HL | null | null | 2,022 | na | Bet v 1 | Regeneron | TBC | TBC | TBC | TBC | Antigen: Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. Also known as REGN5714. | E VQLVE SGGD LV QPGG SLRLSC AASGF TFSSYEMNWVRQ APGKG LEWVSFIS DSSSN IYYAD SVKG RFTIS RDNAKK SLYLQMTSL RAEDT AVYYCARE AIGSTSFDNWGQG TLVTVS S | E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSS LAWYQ QKPGQAPR RLIYS ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAIYYCH QYNNWP LTF GGG TKVEI K |
Unasnemab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGRSLRLSCTASGFTFSDAWMDWVRQAPGKGLEWVAEIRSKANNHATYYAESVKGRFTISRDDSKSIVYLQMNSLRTEDTALYYCTRRDGAYWGKGTTVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFASYFCQQLNTLPWTFGGGTKVEME | na | na | null | null | null | 2,020 | 2021 | RGMA | Mitsubishi Tanabe Pharma Corporation | na | Acute spinal cord injury | na | na | null | E VQLVES GGG LV QPGR SLRLSCT ASGF T FS DAWMDWVRQ APGKGL EWVAEIRS KANNH ATYYAES VKG RFTIS RDDSK SIVYLQM NSLRTEDT ALYYCTR RDGA YW GKG TTVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQD ISSYLNWYQ QKPGKAP KLLIYYT SRLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFASYFCQQL NTLPWTFGGGT KVEM E |
Upanovimab | Whole mAb | G1 | Kappa | Phase-II/III | Active | EVKLVESGGGLVKPGGSLRLSCAASGFTFSNYGMSWVRQAPGKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARFRYDGGGGTVDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASESVDNYGISFMNWFQQKPGQAPRLLIYAASNQGSGVPARFSGSGSGTDFSLTISSLEPEDFAVYFCQQSKEVPRTFGQGTKVEIK | na | na | null | null | 7cyh:ED/7cyp:GF:IH:ED/7cwt:IJ:GF:ED/7e5s:RO | 2,021 | 2022 | SARS-CoV-2 Spike RBD | Sinocelltech | na | COVID-19 | na | na | null | E VKLVES GGG LV KPGG SLRLSC AASGF TFS NYG MSWVR QAPGK RLEWVAEI SSGGS YTY YPDTV TGRFTISR DNAKN TLYLQMNSL RAEDT AVYYCARFRY DGGGG TVDYW GQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCRA SESVDNY GISFMNWF QQKPGQAP RLLIYAA SNQGSGVP ARFS GSGSGTD FSLTIS SLEPED FAVYFCQ QSKEVPRTFGQGT KVEI K |
Upifitamab | Whole mAb | G1 | Kappa | Phase-I/II | Active | QVQLVQSGAEVVKPGASVKMSCKASGYTFTGYNIHWVKQAPGQGLEWIGAIYPGNGDTSYKQKFRGRATLTADTSTSTVYMELSSLRSEDSAVYYCARGETARATFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASQDIGNFLNWYQQKPGKTVKVLIYYTSSLYSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYSKLPLTFGQGTKLELK | na | na | null | null | null | 2,019 | 2020 | SLC34A2 | Mersana Therapeutics | na | Non-small cell lung cancer;Ovarian cancer | na | na | null | Q VQLVQ SGA EVV KPGA SVKMSCK ASGY TFTGYNIHWVK QAPGQG LEWIGAIY PGNGDTSY KQKF RG RATLTA DTSTS TVYMELS SLRSEDS AVYYCA RGET ARATFAYW GQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITCS ASQD IGNFLNWYQ QKPGK TVKVLIYYT SSLYSGVPSRFSGSGSGTD YTLTIS SLQ PEDFATYYCQQ YSKLPL T FGQGT KLEL K |
Urabrelimab | Whole mAb | G4 | Kappa | Phase-I | Discontinued | QVQLQESGPGLVKPSGTLSLTCAVSGVSIRSINWWNWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLNSVTAADTAVYYCARDGGIAVTDYYYYGLDVWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCRASESVSSNLAWYQQKPGQAPRLLIYGAFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSDWFTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | CD47 | Surface Oncology | na | na | Haematological malignancies;Solid tumours | na | null | QV QLQE SGPG LV KPSG TLSLTCAV SG VSIRSINWWNWVR QPPGKGL EWIGEIYH SGSTNYNPSLK SRVTISVD KSKN QFSLKLN S V TAAD TAVYYCA RDGG IAVTDYYYYGLDVW GQG TTVTVS S | E IVLTQ SPA TLSL SPGE RATLSCRA SESVSSN LAWYQ QKPGQAP RLLIYGAF NRATGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYCQ QRSD WFTF GGG TKVEI K |
Urelumab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK | na | na | 6mhr:AB:DE | null | null | 2,010 | 2011 | TNFRSF9 | Bristol-Myers Squibb;National Cancer Institute (USA);Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University of Chicago;Medarex | na | Non-Hodgkin's lymphoma;Solid tumours;Glioblastoma;Multiple myeloma | Colorectal cancer;Head and neck cancer;Malignant melanoma;Non-small cell lung cancer | Medarex UltiMAb Mouse | Jain paper: "VL sequence modified at one position to match patent document (US7659384) and JK germline" | QV QLQQW GAGLLKPSE TLSLTCAVY GGSFSG YYWSWIR QSPEKGL EWIGEI NHGG YVTY NPSLES RVTISVD TSKN QFSLKLSS VTAADT AVYYCAR DYGPGNYD WYFDL WGRG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LA W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPA LTF GGG TKVEI K |
Urtoxazumab | scFv | na | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISTGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDAWGNLDYWGQGTLVTVSS | EIVLTQSPATLSVSPGERATLSCRASQTISNNLHWYQQKPGQAPRLLIKSASQSISGIPARFSGSGSGTDFTLTISSLESEDFAVYYCQQSYSWPLTFGQGTKVEIK | na | na | null | null | null | 2,004 | 2005 | Shiga-like Toxin II | Teijin Pharma | na | na | Haemolytic uraemic syndrome | na | Anti-e coli mAb | E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YG MSWVRQ APGKG LEWVATIS TGGS YTY YPDSVK GRFTISR DNAKN TLYLQMN SLRAEDT AVYYCAR RGDAWGN LDY WGQG TLVTVS S | E IVLTQ SPA TLSV SPGE RATLSCR ASQ TI SNN LHWYQ QKPGQAP RLLIKS ASQS I SGIP ARFS GSGSGTD FTLTISS LESED FAVYYCQ QSYSWP LTF GQGT KVEI K |
Ustekinumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK | na | na | 3hmw:HL/3hmx:HL | null | null | 2,008 | 2009 | IL12B | Centocor Inc;Janssen Biotech;Medarex | Crohn's disease;Plaque psoriasis;Psoriatic arthritis | Ulcerative colitis;Spondylarthritis;Systemic lupus erythematosus;Atopic dermatitis | Multiple sclerosis;Palmoplantar pustulosis;Primary biliary cirrhosis;Rheumatoid arthritis;Sarcoidosis | Medarex UltiMAb Mouse | null | E VQLVQ SGA EVK KPGE SLKISC KGSGYS FTTYWLGWVR QMPGKGLD WIGIM SPVDSDI RY SPSFQG QVTMSV DKS ITTAYLQWN SLKASDT AMYYCAR RRPGQG YFDFW GQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISSWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATYYCQQ YNIY P Y T FGQGT KLEI K |
Utomilumab | Whole mAb | G2 | Lambda | Phase-II | Active | EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS | SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL | na | na | 6a3w:GH:DE:AB:JK/6mi2:DE:AB | null | null | 2,016 | 2017 | TNFRSF9 | Dana-Farber Cancer Institute;Immatics US;Kite Pharma;Kyowa Hakko Kirin;M. D. Anderson Cancer Center;Pfizer | na | Breast cancer;Oropharyngeal cancer;Solid tumours;B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Ovarian cancer | Non-Hodgkin's lymphoma;Colorectal cancer | MorphoSys HuCAL Phage Display | null | E VQLVQ SGA EVK KPGE SLRISC KGSGYS FSTYWISWVR QMPGKGL EWMGKI YPGDSYTNYSPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYCA RGY GIFD YWGQG TLVTV SS | SYELTQPPS VSV SPGQ TASITC SGDNIGDQ YAHWYQ QKPGQSP VLVIYQ DKNRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCATY TGFG SLAVF GGGT KLTV L |
Vadastuximab | Whole mAb ADC | G1 | Kappa | Phase-III | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKYNEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTINCKASQDINSYLSWFQQKPGKAPKTLIYRANRLVDGVPSRFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIK | na | na | null | null | null | 2,015 | 2016 | CD33 | Seattle Genetics | na | na | Acute myeloid leukaemia;Myelodysplastic syndromes | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYDINWVR QAPGQG LEWIGWIY PGDGSTKYNEK FKAKATLTA DTSTS TAYMELRSL RSDDT AVYYCA SGYEDAMDYWGQG TTVTVS S | DIQ M TQSPSS LSA SVGD RVTINCK ASQD INSYLSWFQ QKPGKAPK TLIYRA N RLV DGVPS RF SGSGSGQD YTLTISS LQPEDF ATYYCLQ YDEFP LTF GGG TKVEI K |
Valanafusp | Whole mAb Fusion | G1 | Kappa | Phase-II | Active | QVQLQQSGPELVKPGALVKISCKASGYTFTNYDIHWVKQRPGQGLEWIGWIYPGDGSTKYNEKFKGKATLTADKSSSTAYMHLSSLTSEKSAVYFCAREWAYWGQGTLVTVSA | DIQMTQSPSSLSASLGERVSLTCRASQDIGGNLYWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYSSSPWTFGGGTKMEIK | na | na | null | 5kqv:PQ:CD/4zxb:CD | 3loh:CD/2dtg:CD/3w14:CD:PQ | 2,017 | 2018 | INSR | ArmaGen Technologies | na | Mucopolysaccharidosis I | na | na | null | QV QLQ QSGPE LV KPGA LVKISCK ASGY TFTNYDIHWVKQ RPGQG LEWIGWIY PGDGSTKYNEKFKG KATLTA DKSSS TAYMHLS SLTSEKS AVYFCAREWAYW GQG TLVTVS A | DI QMT QSPSS LS ASLGE RVSLTCRA SQDIGGN LYWLQQ GPDGT IKRLIYAT SSLDSGVPK R FSGSRSGSD YSLTISS LESEDF VDYYCLQY SSSPW T FGGGT KMEI K |
Vandortuzumab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAVSGYSITSDYAWNWVRQAPGKGLEWVGYISNSGSTSYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARERNYDYDDYYYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKSSQSLLYRSNQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYNYPRTFGQGTKVEIK | na | na | null | null | null | 2,014 | 2015 | STEAP1 | Roche;Genentech | na | na | Cancers;Prostate Cancer | na | null | E VQLVES GGG LV QPGG SLRLSCAV SGY SI TSD YAWNWVR QAPGKGL EWVGYIS NSGSTSYNPSLK SRFTISR DTSKN TLYLQMN SLRAEDT AVYYCAR ERNYDYDD YYYAMD YWGQG TLVTV SS | DI QMT QSPSS LSA SVGD RVTITC KSSQ SLLYR SNQKN YLAWYQ QKPGKAP KLLIYWAS TRESGVPS RF SGSGSGTD FTLTIS SLQP EDFAT YYCQ Q Y YNYPRTFGQGT KVEI K |
Vantictumab | Whole mAb | G2 | Lambda | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYTLSWVRQAPGKGLEWVSVISGDGSYTYYADSVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARNFIKYVFANWGQGTLVTVSS | DIELTQPPSVSVAPGQTARISCSGDNIGSFYVHWYQQKPGQAPVLVIYDKSNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYANTLSLVFGGGTKLTVL | na | na | null | null | null | 2,013 | 2014 | FZD Family | Bayer HealthCare Pharmaceuticals;OncoMed Pharmaceuticals | na | na | Breast cancer;Non-small cell lung cancer;Pancreatic cancer | MorphoSys HuCAL Phage Display | null | E VQLVES GGG LV QPGG SLRLSCA ASGF TFSHYTLSWVR QAPGKG LEWVSVIS GDGS YTYYA DSVKG RFTISS DNSKN TLYLQMN SLRAEDT AVYYC AR N FI KYVFA NWGQG TLVTV SS | DIELTQPPS VSV APGQ TARISC SGDNIG SFYVHWYQ QKPGQAP VLVIY DKSNRPSGIPERFSGSNSGN TATLTIS GTQAEDEAD YYCQ SYAN TLSLVF GGGT KLTV L |
Vanucizumab | Bispecific mAb | G1;G1 | Lambda;Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS | QPGLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL | EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK | 4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ | None;None | None;6bft:AB:HL/1cz8:HL:YX | 2,014 | 2015 | ANGPT2;VEGFA | Roche | na | na | Solid tumours;Colorectal cancer | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQG LEWMGWI NPNSGGTNY AQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCA RSPNPYY Y DSSGY Y YPGA FDIW GQG TMVTVS S | QPGLTQPP SVSV APGQ TARITC GGNNIGSK SVHWYQ QKPGQAP VLVVY DDSDRPSGIPE R FSGSNSGN TATLTISRVE AGDE ADYYCQVWD SSSD HYVFG TGT KVTV L |
Varisacumab | Whole mAb | G1 | Kappa | Phase-II/III | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGRSMVRGVIIPFNGMDVWGQGTTVTVSS | DIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK | na | na | null | null | null | 2,016 | 2017 | VEGFA | Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS | na | na | Breast cancer;Colorectal cancer;Eye disorders;Glioblastoma;Non-small cell lung cancer | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGGT FSSYAISWVR QAPGQG LEWMG G F DPEDGE TIYAQKF QG RVTMT EDTSTDT AYMELS SLRSEDT AVYYC ATGR SMVRGVIIP FNGM DV WGQG TTVTVS S | DIR MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSYSTP LTF GGG TKVEI K |
Varlilumab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGNWGFFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNTYPRTFGQGTKVEIK | na | na | null | null | null | 2,014 | 2015 | CD27 | Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia | na | Malignant melanoma;Solid tumours;Non-Hodgkin's lymphoma;Renal cell carcinoma;Glioblastoma | Haematological malignancies;Prostate cancer;Breast cancer;Ovarian cancer;Glioma | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y DMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RGSGN WGFFD YWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISRWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATYYCQQ YNTYPRTFGQGT KVEI K |
Varokibart | Whole mAb | G4 | Lambda | TBC | Active | QVQLQESGPGLVKPSQTLSLTCTVSGGSISNGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASLGNWFDYWGQGTLVTVSS | SYVLTQPPSVSVAPGQTARITCGGNNIGSKNVYWYQQKPGQAPVLVVHDDSDRPSGIPERFSGSNSGNTATLTISRVEVGDEADYSCQVWDSSSDHVVFGGGTKLTVL | na | na | null | null | null | 2,022 | na | IL5 | TBC | TBC | TBC | TBC | TBC | null | QV QLQE SGPGLVKPSQ TLSLTCTV SGGSISNGG YYWSWIR QHPGKGL EWIGYIYYS GST Y YNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA SLGNW FD YWGQG TLVTVS S | SY VL TQPPS VSV APGQ TARITC GGNNIGSK NVYWYQ QKPGQAP VLVVH DDSDRPSGIPE R FSGSNSGN TATLTISRVE VGDE ADYSCQVWD SSSD HVVFG GGT KLTV L |
Vatelizumab | Whole mAb | G4 | Kappa | Phase-II/III | Discontinued | QVQLQESGPGLVKPSETLSLTCTVSGFSLTNYGIHWIRQPPGKGLEWLGVIWARGFTNYNSALMSRLTISKDNSKNQVSLKLSSVTAADTAVYYCARANDGVYYAMDYWGQGTLVTVSS | DFVMTQSPAFLSVTPGEKVTITCSAQSSVNYIHWYQQKPDQAPKKLIYDTSKLASGVPSRFSGSGSGTDYTFTISSLEAEDAATYYCQQWTTNPLTFGQGTKVEIK | na | na | null | null | null | 2,011 | 2012 | ITGA2 | Chromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi | na | na | Cancer;Chronic obstructive pulmonary disease;Multiple sclerosis;Retinal disorders;Rheumatoid arthritis;Ulcerative colitis | na | null | QV QLQE SGPGL V KPSE TLSLTCTV SGF SL TN YGIHWIR QPPGKGL EWLGVIWAR GFTNYNSA LMSRLTIS KDNSKN QVSLKLSS VTAADT AVYYCAR ANDG VYYAMDY WGQG TLVTVS S | DF VMT QSP AFLSV TPGE KVTITCS AQSS VNYIHWYQ QKPDQAPK KLIYD TSKLASGVPS RF SGSGSGTD YTFTISS LEAEDA ATYYCQQW TTNPL T FGQGT KVEI K |
Vedolizumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS | DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIK | na | na | null | null | null | 2,008 | 2009 | ITGA4_ITGB7 | Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology | Crohn's disease;Ulcerative colitis | Graft-versus-host disease;Coeliac disease | Malignant melanoma | na | null | Q VQLVQ SGA EVK KPGA SVKVSC KGSG YTFTSYWMHWVR QAPGQ RLEWIGEI DPSESNTNYNQKFKG RVTLTVDI SAST AYMELSS LRSEDT AVYYCA RGGYDGW DYAIDY WGQG TLVTVS S | DV VMT QSPLSLPVTPGEPA SISCR SSQ SLAK SYGN TYLSWYL QKPGQSP QLLIYGI SNRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCL QGTHQPY T FGQGT KVEI K |
Veltuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS | DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK | na | na | null | null | null | 2,007 | 2008 | MS4A1 | Immunomedics;Weill Cornell Medical College | na | na | Chronic lymphocytic leukaemia;Rheumatoid arthritis;Idiopathic thrombocytopenic purpura;Non-Hodgkin's lymphoma;Follicular lymphoma | na | null | Q VQLQQ SGA EVK KPGS SVKVSCK ASGY TFTSYNMHWVK QAPGQG LEWIGAI YPGMGDTSYNQK F KG KATLTA DESTN TAYMELS SLRSEDT AFYYCAR S T YYGGD WYFDVW GQG TTVTVS S | DI QLT QSPSS LSAS VGD RVTMTCR ASSS VSYIHWFQ QKPGKAPKP WIYAT SNLASGV PVRFS GSGSGT DYTFTISS LQ PEDIA TYYCQQ WTSNPPTFGGGT KLEI K |
Vepsitamab | Bispecific scFv-scFv-scFc | na;na | Lambda;Lambda | Phase-I | Active | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKCLEWIGDIDASGSTKYNPSLKSRVTISLDTSKNQFSLKLNSVTAADTAVYFCARKKYSTVWSYFDNWGQGTLVTVSS | SYELTQPSSVSVPPGQTASITCSGDKLGDKYASWYQQKPGQSPVLVIYQDRKRPSGVPERFSGSNSGNTATLTISGTQAMDEADYYCQAWGSSTAVFGCGTKLTVL | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,021 | 2022 | MUC17;CD3E | Amgen | na | GE Junction Cancer;Gastric Adenocarcinoma | na | BiTE Technology | null | QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGK CLEWIGDI DASGSTKYNPSLKS RVTISLD TSKN QFSLKL N S VTAADT AVYFCA RKKYS TVWSYF DNWGQG TLVTVS S | SYELTQPS SVS VPPGQ TASITC SGDKLGDK YA S WYQ QKPGQSP VLVIYQ DRKRPSGVPERFSGSNSGN TATLTIS GTQAMDEAD YYCQA WGSST AVF GCGT KLTV L |
Vesencumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSQISPAGGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGELPYYRMSKVMDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQYFSSYLAWYQQKPGKAPKLLIYGASSRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLGSPPTFGQGTKVEIK | na | na | 2qqn:HL | null | null | 2,010 | 2011 | NRP1 | Genentech;Roche | na | na | Solid tumours | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSQI SPAGGYTNYADSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYC ARGELP YYRMSKVMDV WGQG TLVTVS S | DIQ M TQSPSS LSA SVGD RVTITCR AS QYFSSYLAWYQ QKPGKAP KLLIYG ASSRASGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQY LGSPPTFGQGT KVEI K |
Vibecotamab | Bispecific Mixed mAb and scFv | G1;G1 | Kappa;Kappa | Phase-I | Discontinued | QVQLQQSGAEVKKPGASVKVSCKASGYTFTDYYMKWVKQSHGKSLEWMGDIIPSNGATFYNQKFKGKATLTVDRSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS | DFVMTQSPDSLAVSLGERATINCKSSQSLLNTGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGGGTKLEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK | None;None | None;None | None;None | 2,018 | 2019 | IL3RA;CD3E | Xencor | na | na | Haematological malignancies | na | null | QV QLQQ SGA EVK KPGA SVKVSCK ASGY TF TDYYMKW VK QSHGKS LEWM GD II PSNGA TFY NQKFKG KATLTVD RSTS TAYMELS SLRSEDT AVYYC ARSHL LRASWFAYW GQG TLVTVS S | DF VMT QSPDS LAVS LGER ATINC KSSQS LL NTGNQKN YLTWYQ QKPGQPP KLLIYWAS TRESGVPDR F TGSGSGTD FTLTISS LQAED VAVYYC QNDYSYPY T FGGGT KLEI K |
Vibostolimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYVMHWVRQAPGQGLEWIGYIDPYNDGAKYAQKFQGRVTLTSDKSTSTAYMELSSLRSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASEHIYSYLSWYQQKPGKVPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHHFGSPLTFGQGTRLEIK | na | na | null | null | null | 2,019 | 2020 | TIGIT | Merck | na | Solid tumours;Non-small cell lung cancer;Malignant melanoma | na | na | null | E VQLVQ SGA EVK KPGS SVKVSCK ASGY TFSSYVMHWVR QAPGQG LEWIGYI DPYNDGA KYA QK FQG RVTLTS DKSTS TAYMELS SLRSEDT AVYYCA RGGPY GWYFDV WGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASEH IYSYLSWY QQKPGKVP KLLIYN AK T LAEGVPSRFSGSGSGTD FTLTIS SLQ PEDVATY YC Q HHFGSPL T FGQGT RLEI K |
Vilamakitug | Whole mAb | G4 | Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGRFTNYAILWVRQAPGQGLQWLGGIIPIFDETDHAQDFQDRLTITVDESMTTAYMELSSLRPEDTAIYYCATGSNSYYGLYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPSTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | IL1A | XBiotech USA, Inc | na | Pancreatic cancer;Arthritis;Colorectal cancer | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGR FTNYAILWVRQ APGQG LQWLGGIIPIF DETDHAQDFQD RLTITV DESMT TAYMELS SLRPEDT AIYYCA TGSNS YYGLYW GQG TLVTVS S | D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYS SNNK NYLAWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQY YSTPSTFGQGT KVEI K |
Vilobelimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLQQSGPQLVRPGTSVKISCKASGYSFTTFWMDWVKQRPGQGLEWIGRIDPSDSESRLDQRFKDRATLTVDKSSSTVYMQLSSPTSEDSAVYYCARGNDGYYGFAYWGQGTLVTVSS | DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMKWYQQKPGQPPKLLIYAASNLQSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK | na | na | null | null | null | 2,019 | 2020 | C5 | InflaRX | na | Hidradenitis suppurativa;Inflammation;COVID-19;Microscopic polyangiitis;Pyoderma gangrenosum;Sepsis;Systemic inflammatory response syndrome;Squamous cell cancer | Inflammation | na | Chimeric | QV QLQ QSGP QLV RPGT SVKISCK ASGY SFTTFWMDWVK QRPGQG LEWIGRI DPSDSESRLDQRFKDR ATLTVD KSSS TVYMQL SSPTSEDS AVYYCAR GNDG YYGFAYW GQG TLVTVS S | D IVLT QSPA SLAVS LGQ RATISCK ASQ SV DYDGD SYMKWYQ QKPGQPP KLLIYAA SNLQSGIP ARFS GSGSGTD FTLNIHP VEEEDA A TYYCQ QSNEDPYTFGGGT KLEI K |
Visilizumab | Whole mAb | G2 | Kappa | Phase-III | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK | na | na | null | null | null | 2,000 | 2001 | CD3E | PDL BioPharma | na | na | Crohn's disease;Graft-versus-host disease;Psoriasis;Renal transplant rejection;Ulcerative colitis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFISYTMHWVR QAPGQG LEWMGYI NPRSGY TH YNQKLKDK ATLTA DKSAS TAYMELS SLRSEDT AVYYCAR S AYY DYDGF AYW GQG TLVTV SS | DI QMT QSPSS LSAS VGD RVTITCS ASSS VSYMNWY QQKPGKAPK RLIYD TSKLASGVPS RF SGSGSGT DFTLTISS LQPE DF ATYYCQQ WSSNPPTFGGGT KVEI K |
Visugromab | Whole mAb | G4 | Kappa | Phase-I | Active | QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPTLKSRLTITKDPSKNQVVLTMTNMDPVDTATYYCARSSYGAMDYWGQGTLVTVSS | DIVLTQSPSFLSASVGDRVTITCKASQNVGTNVAWFQQKPGKSPKALIYSASYRYSGVPDRFTGSGSGTEFTLTISSLQPEDFAAYFCQQYNNFPYTFGGGTKLEIK | na | na | null | null | null | 2,022 | na | GDF15 | CatalYm | na | Solid tumours | na | na | null | Q ITLK ESGP TLV KPTQ TLTLTCTF SG FSLS TSGM GVSWIR QPPGKGL EWLAHIYW DDDKRYNPTL KSRLTITK DPSKN QVVLTMT NMDPVDT ATYYCAR SSYGAMDYWGQG TLVTVS S | D IVLT QSPS FLSA SVGD RVTITCK ASQNVGT NVAWFQ QKPGKSPK ALIYSASYRY SGVPDR F TGSGSGT EFTLTIS SLQ PEDFAAYFCQQ YNNFPY T FGGGT KLEI K |
Vixarelimab | Whole mAb | G4-G1 | Lambda | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYEINWVRQATGQGLEWMGWMNPNSGYTGYAQKFQGRVTMTRDTSISTAYMEMSSLRSEDTAVYYCARDIVAANTDYYFYYGMDVWGQGTTVTVSS | QSVLTQPPSASGTPGQRVTISCSGSNSNIGSNTVNWYHQLPGTAPKLLIYNINKRPSGVPDRFSGSKSGSSASLAISGLQSEDEADYYCSTWDDSLDGVVFGGGTKLTVL | na | na | null | null | null | 2,020 | 2021 | OSMR | Kiniksa Pharmaceuticals | na | Prurigo nodularis;Pruritus;Atopic dermatitis | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYEINWVRQ ATGQG LEWMGWM NPNSGYT GYAQKF QG RVTMT RDTS ISTAYMEMS SLRSEDT AVYYCA RD IVA ANTD YYFYYGMD VWGQG TTVTVS S | QSVLTQPPSASGTPGQ RVTISC SGSNSNIGSN TVNWYH QLPGTAP KLLIYN INKRPSGVPDRFSGSKSGSS ASLAI SGLQSEDEAD YYC STWDDSLDG VVF GGGT KLTV L |
Vixtimotamab | Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody) | na;na | Kappa;Lambda | Phase-I | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWMNPNSGNTGFAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDRANTDYSLGMDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSTGAVTTSNYANWVQQKPGKAPKALIGGTNKRAPGVPSRFSGSLIGDKATLTISSLQPEDFATYYCALWYSNLWVFGQGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSYFAYWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSRSNIGSNTVNWYQQLPGTAPKLLIYGNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLIGWVFGGGTKVTVL | None;None | None;None | None;None | 2,020 | 2021 | CD3E;CD33 | Amphivena Therapeutics | na | Acute myeloid leukemia;Myelodysplastic syndromes | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYDINWVR QAPGQG LEWMGWM NPNSGNTGF AQKF QG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCAR DRANTDY SLGMDV WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR SSTGA VTT SN YANWVQ QKPGKAPK ALI GGTNKRAPGVPSRFSG SL IGDK ATLTISS LQP EDFAT YYCALWY SN LWVF GQGT KVEI K |
Vobarilizumab | Bispecific Single Domains (VH-VH') | na;na | na;na | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGSVFKINVMAWYRQAPGKGRELVAGIISGGSTSYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCAFITTESDYDLGRRYWGQGTLVTVSS | na | EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS | na | None;None | None;None | None;None | 2,015 | 2016 | IL6R;ALB | Ablynx | na | na | Rheumatoid arthritis;Systemic lupus erythematosus | Nanobody Technology | null | E VQLVES GGG LV QPGG SLRLSC AASGS VFKINVMAWYR QAPGKGR ELVAGIIS GGSTSYADSVK GRFTISR DNAKN TLYLQMN SLRPEDT AVYYCAFIT TESDYDLGRR YW GQG TLVTVS S | null |
Vobramitamab | Whole mAb | G1 | Kappa | Phase-I/II | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATINSGGSNTYYPDSLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHDGGAMDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASESIYSYLAWYQQKPGKAPKLLVYNTKTLPEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPPWTFGQGTRLEIK | na | na | null | null | null | 2,022 | na | CD276 | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFSS YG MSWVRQ APGKG LEWVATIN SGGSNT Y YPDSLKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCAR HDGGAMDYWGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASES IYSYLAWY QQKPGKAP KLLVYN TKTLPEGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYY C Q HHYGTPPWTFGQGT RLEI K |
Vofatamab | Whole mAb | G1 | Kappa | Phase-I/II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFTSTGISWVRQAPGKGLEWVGRIYPTSGSTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTYGIYDLYVDYTEYVMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVDTSLAWYKQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGHPQTFGQGTKVEIK | na | na | null | null | 4wv1:BA:ED/3grw:HL | 2,018 | 2019 | FGFR3 | BioClin Therapeutics;Rainier Therapeutics | na | Urogenital cancer | Multiple myeloma;Solid tumours;Achondroplasia | na | null | E VQLVES GGG LV QPGG SLRLSC AASG FTFTS T GISWVRQ APGKG LEWVGRIY PTSGSTNYADSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCA RTYG IYDLYVD YT EYVMD YWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQDVDTS LAWYK QKPGKAP KLLIYSASFLY SGVPSRFSGSGSGTD FTLTIS SLQPED F ATYYCQ QSTGHPQTFGQGT KVEI K |
Volagidemab | Whole mAb | G2 | Kappa | Phase-II | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMWYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSVQPEDFVTYYCLQHNSNPLTFGGGTKVEIK | na | na | null | 4lf3:ED:BA/5xf1:HL:CD/5xez:CD:HL/4ers:HL | null | 2,018 | 2019 | GCCR | Amgen;REMD Biotherapeutics | na | Type 1 diabetes mellitus;Type 2 diabetes mellitus;Metabolic disorders;Glucose intolerance | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVMWY DGSNKD YVD S V KG RFTISR DNSKN TLYLQMNRL RAEDT AVYYCA REKDH YDIL TGYN YYYGLDVW GQG TTVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASQGIRNDLG WYQ QKPGKAPK RLIYAA SSLQSGVPS RF SGSGSGT EFTLTISS VQPED FVTYYCLQ HNSNPL TF GGG TKVEI K |
Volociximab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | QVQLKESGPGLVAPSQSLSITCTISGFSLTDYGVHWVRQPPGKGLEWLVVIWSDGSSTYNSALKSRMTIRKDNSKSQVFLIMNSLQTDDSAMYYCARHGTYYGMTTTGDALDYWGQGTSVTVSS | QIVLTQSPAIMSASLGERVTMTCTASSSVSSNYLHWYQQKPGSAPNLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYLRSPPTFGGGTKLEIK | na | na | null | null | null | 2,005 | 2006 | a5b1 Integrin | Abbott Biotherapeutics Corp;Biogen Idec;IVERIC bio;National Cancer Institute (USA);PDL BioPharma | na | na | Age-related macular degeneration;Intestinal cancer;Non-small cell lung cancer;Peritoneal cancer;Malignant melanoma;Pancreatic cancer;Renal cell carcinoma | na | null | Q VQLKE SGPGL V APSQ SLSITCTI SGF SL TDY GVHWVR QPPGKGL EWLVVIW SDGSSTYNSAL KSRMTIR KDNSKS QVFLIMN SLQTDDS AMYYCA RHGT YYGMT TTGDA L DYWGQGT SVTV SS | Q IVLT QSPA IMSA SLGE RVTMTCTA SSSVSSN YLHWYQ QKPGSAPN LWIYS TSNLASGVP ARFS GSGSGT SYSLTISS MEAEDA ATYYCHQYL RSPPTFGGGT KLEI K |
Volrustomig | Bispecific mAb | G1 | Kappa;Kappa | Phase-II | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS | QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK | 5ggu:HL:AB/5ggv:HL;None | None;None | None;None | 2,022 | na | CTLA4;PDCD1 | AstraZeneca | na | Solid tumours;Renal cell carcinoma | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCAR DPRGA TLYYYYY G M DVWGQG TTVTVS S | DIQ M TQSPSS LSA SVGD RVTITCR ASQS INSYLDWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YYSTPF T FGPGT KVEI K |
Vonlerolizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK | na | na | 6okn:AB:CD/6ogx:CD | null | null | 2,015 | 2017 | TNFRSF4 | Genentech | na | na | Solid tumours;Urogenital cancer | na | Vonlerolizumab is the new name for Pogalizumab (PL116) | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT DS YMSWVR QAPGQGL EWIGD MYPDNGDSSYNQKF RERVTITR DTSTS TAYLELSS LRSEDT AVYYCVL APR WYFSVW GQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLNWYQ QKPGKAP KLLIYYT SRLRSGVPS R FSGSGSGTD FTLTIS SLQ PEDFAT YYC QQGHTLPPTFGQGT KVEI K |
Vopratelimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMDWVRQAPGKGLVWVSNIDEDGSITEYSPFVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCTRWGRFGFDSWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLSGSFNYLTWYQQKPGQPPKLLIFYASTRHTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHHHYNAPPTFGPGTKVDIK | na | na | null | null | null | 2,017 | 2018 | ICOS | Jounce Therapeutics | na | Solid tumours;Urogenital cancer;Non-small cell lung cancer | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGFT F S DYWMDWVRQ APGKG LVWVSNI DEDGS ITEY SPFVKG RFTISR DNAKN TLYLQMN SLRAEDT AVYYCT RWGR F G F DSWGQG TLVTVS S | D IVMT QSPDS LAVS LGE RATINC KSSQSLLSGS FNYLTWYQ QKPGQPP KLLIFYA STRHTGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCH HHYNAPPTFGPGT KVDI K |
Vorsetuzumab | Whole mAb ADC | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS | DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK | na | na | null | null | null | 2,012 | 2013 | CD70 | Seattle Genetics | na | na | Autoimmune disorders;Cancer;Inflammation;Plaque psoriasis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTN YG MNWVRQ APGQG LKWMGWIN TYTGEPTY AD AFKG RVTMT RDTS ISTAYMELSR LRSDDT AVYYCA RDYGDYGMDYWGQG TTVTVS S | D IVMT QSPDS LAVS LGER ATINCR ASKSVSTSGY SFMHWYQ QKPGQPP KLLIYLA SNLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QHSREVPW T FGQGT KVEI K |